Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Revenue (2016 - 2025)

CorMedix (CRMD) has disclosed Revenue for 14 consecutive years, with $128.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 312.1% to $128.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311.7 million through Dec 2025, up 617.2% year-over-year, with the annual reading at $311.7 million for FY2025, 617.03% up from the prior year.
  • Revenue hit $128.6 million in Q4 2025 for CorMedix, up from $104.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $128.6 million in Q4 2025 to a low of -$13113.0 in Q3 2023.
  • Historically, Revenue has averaged $18.7 million across 5 years, with a median of $38088.0 in 2021.
  • Biggest five-year swings in Revenue: crashed 292.36% in 2023 and later surged 397473.23% in 2025.
  • Year by year, Revenue stood at $56397.0 in 2021, then plummeted by 47.33% to $29702.0 in 2022, then crashed by 144.15% to -$13113.0 in 2023, then skyrocketed by 238106.3% to $31.2 million in 2024, then surged by 312.1% to $128.6 million in 2025.
  • Business Quant data shows Revenue for CRMD at $128.6 million in Q4 2025, $104.3 million in Q3 2025, and $39.7 million in Q2 2025.